The stock of Fresenius Medical Care AG ADR (FMS) has gone down by -5.11% for the week, with a -0.69% drop in the past month and a 4.02% rise in the past quarter. The volatility ratio for the week is 1.22%, and the volatility levels for the past 30 days are 1.27% for FMS. The simple moving average for the past 20 days is -4.92% for FMS’s stock, with a 8.43% simple moving average for the past 200 days.
Is It Worth Investing in Fresenius Medical Care AG ADR (NYSE: FMS) Right Now?
Fresenius Medical Care AG ADR (NYSE: FMS) has a price-to-earnings ratio of 18.90x that is above its average ratio. Additionally, the 36-month beta value for FMS is 0.99. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 3 rating it as “hold,” and 1 rating it as “sell.”
The public float for FMS is 586.39M and currently, short sellers hold a 0.14% ratio of that float. The average trading volume of FMS on February 21, 2025 was 241.80K shares.
FMS) stock’s latest price update
Fresenius Medical Care AG ADR (NYSE: FMS)’s stock price has soared by 0.31 in relation to previous closing price of 22.94. Nevertheless, the company has seen a loss of -5.11% in its stock price over the last five trading days. accessnewswire.com reported 2025-02-10 that The Company’s patent pending silicon-enhanced spheroidized graphite technology represents a breakthrough in lithium-ion battery performance. OTTAWA, ON / ACCESS Newswire / February 10, 2025 / Focus Graphite Advanced Materials Inc. (TSXV:FMS)(OTCQB:FCSMF)(FSE:FKC) (“Focus” or the “Company”), a Canadian critical minerals resource company developing innovative advanced battery materials and technology, is pleased to provide an update on the status of its patent applications for its proprietary silicon-enhanced spheroidized graphite technology for lithium-ion battery anodes.
Analysts’ Opinion of FMS
Berenberg, on the other hand, stated in their research note that they expect to see FMS reach a price target of $25.60. The rating they have provided for FMS stocks is “Buy” according to the report published on November 06th, 2024.
FMS Trading at -2.07% from the 50-Day Moving Average
After a stumble in the market that brought FMS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.87% of loss for the given period.
Volatility was left at 1.27%, however, over the last 30 days, the volatility rate increased by 1.22%, as shares sank -4.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.24% lower at present.
During the last 5 trading sessions, FMS fell by -4.99%, which changed the moving average for the period of 200-days by +9.87% in comparison to the 20-day moving average, which settled at $24.20. In addition, Fresenius Medical Care AG ADR saw 1.63% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for FMS
Current profitability levels for the company are sitting at:
- 0.08 for the present operating margin
- 0.25 for the gross margin
The net margin for Fresenius Medical Care AG ADR stands at 0.03. The total capital return value is set at 0.06. Equity return is now at value 4.76, with 1.93 for asset returns.
Based on Fresenius Medical Care AG ADR (FMS), the company’s capital structure generated 0.45 points at debt to capital in total, while cash flow to debt ratio is standing at 0.2. The debt to equity ratio resting at 0.82. The interest coverage ratio of the stock is 3.95.
Currently, EBITDA for the company is 3.21 billion with net debt to EBITDA at 3.08. When we switch over and look at the enterprise to sales, we see a ratio of 1.18. The receivables turnover for the company is 5.87for trailing twelve months and the total asset turnover is 0.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.37.
Conclusion
In conclusion, Fresenius Medical Care AG ADR (FMS) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
